The company from Israel will advance its liquid biopsy platform further.
Senseera, an Israeli-based company pioneering chromatin epigenomics, has raised $7.1M in a seed funding round. The funding will accelerate the development and global expansion of its liquid biopsy platform.
The round was led by Lightspeed Venture Partners, with participation from I-Next Capital and the Lowy Medical Research Institute.
Revolutionizing disease diagnosis and monitoring
With applications in oncology, immunology and metabolic diseases, the platform is supported by data from over 20,000 human samples. Senseera’s technology provides real-time insights into tissue and immune cell states, enabling personalized treatments and accelerating drug development.
A bold step toward improved patient outcomes
The funds will support the market entry of Senseera’s next-generation transplant rejection test, the expansion of its liver disease diagnostics pipeline, and the advancement of clinical trials.
About the DayOne Health 4.0 accelerator
Congratulations to the Senseera team, who are part of the ongoing DayOne Health 4.0 accelerator.
DayOne Health 4.0 is a six-month hybrid accelerator for startups at the intersection with pharma clinical development, in the Basel Area, Europe’s life science hub.
